DOCSLIB.ORG

Nausea and Vomiting and to Manage Breakthrough Symptoms

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

6/16/2015 DISCLOSURES ● Leah Edenfield declares no conflicts of interest, real or apparent, CHEMOTHERAPY TOXICITY AND and no financial interests in any company, product, or service SUPPORTIVE CARE: mentioned in this program, including grants, employment, gifts, MANAGEMENT OF stock holdings, and honoraria. GASTROINTESTINAL SYMPTOMS Leah Edenfield, PharmD, BCPS PGY2 Oncology Pharmacy Resident June 12, 2015 OBJECTIVES Identify gastrointestinal effects frequently associated with chemotherapy Design a strategy to prevent chemotherapy-induced nausea and vomiting and to manage breakthrough symptoms Recommend over-the-counter medications for diarrhea and NAUSEA AND VOMITING constipation as well as treatments for refractory symptoms Evaluate appetite stimulants for oncology patients Select appropriate therapy for management of mucositis PATHOPHYSIOLOGY CONTRIBUTING CAUSES Impulses to the vomiting center come from the chemoreceptor trigger zone, pharynx and GI tract, and cerebral cortex Bowel obstruction Impulses are then sent to the salivation center, abdominal muscles, Vestibular dysfunction respiratory center, and cranial nerves Hypercalcemia, hyperglycemia, or hyponatremia Uremia Opiates or other concomitant mediations Gastroparesis Anxiety Serotonin and dopamine receptors are involved in the emetic response and are activated by chemotherapy Other relevant receptors include acetylcholine, corticosteroid, histamine, cannabinoid, opiate, and neurokinin-1 receptors in the vomiting and vestibular centers Antiemesis. NCCN Guidelines. Version 1.2015. Antiemesis. NCCN Guidelines. Version 1.2015. Image available at www.aloxi.net 1 6/16/2015 EMETIC RISK OF CHEMOTHERAPY ASCO GUIDELINES: EMETIC RISK Emetic risk categories .High (>90%) .Moderate (30-90%) .Low (10-30%) .Minimal (<10%) *Anthracycline + cyclophosphamide = high risk American Society of Clinical Oncology 2011. www.asco.org/guidelines/antiemetics. American Society of Clinical Oncology 2011. www.asco.org/guidelines/antiemetics. ASCO GUIDELINES: MANAGEMENT ASCO GUIDELINES: MANAGEMENT High Risk Breakthrough nausea and vomiting despite appropriate •NK1 antagonist: fosaprepitant 150mg or aprepitant 125mg day 1 and 80mg prophylaxis days 2-3 •5-HT3 receptor antagonist day 1 . Add lorazepam or alprazolam •Dexamethasone 12mg day 1 and 8mg days 2-3 or 2-4 . Add olanzapine Moderate Risk . Substitute metoclopramide for 5-HT3 receptor antagonist •Palonosetron 0.25g IV or 0.5g PO day 1 (alternatively may use another 5-HT3 . Add dopamine antagonist receptor antagonist ) •Dexamethasone 8mg IV or PO days 1-3 Low Risk •Dexamethasone 8mg Minimal Risk •No routine antiemetic American Society of Clinical Oncology 2011. www.asco.org/guidelines/antiemetics. American Society of Clinical Oncology 2011. www.asco.org/guidelines/antiemetics. NCCN GUIDELINES: HIGH EMETIC RISK NCCN GUIDELINES: MODERATE RISK Aprepitant- Netupitant- Olanzapine- Aprepitant- Netupitant- Olanzapine- containing regimen containing regimen containing regimen containing regimen containing regimen containing regimen •Aprepitant 125mg PO •Netupitant 300mg/ •Olanzapine 10mg PO •5-HT3 antagonist AND • Netupitant 300mg/ • Olanzapine 10mg PO day 1 and 80mg PO day palonosetron 0.5mg PO days 1-4 dexamethasone day 1 palonosetron 0.5mg PO days 1-3 2-3 once •Palonosetron 0.25mg IV •5-HT3 antagonist OR once • Palonosetron 0.25mg IV OR Fosaprepitant • Dexamethasone 12mg once dexamethasone days 2-3 • Dexamethasone 12mg once PO/IV day 1 and 8mg 150mg IV once PO/IV day 1 and 8mg • Dexamethasone 20mg • With or without • Dexamethasone 20mg IV PO/IV days 2-4 aprepitant or PO/IV days 2-3 once •5-HT3 antagonist day 1 IV once fosaprepitant then • Dexamethasone days 1- dexamethasone days 2-3 4 Antiemesis. NCCN Guidelines. Version 1.2015. Antiemesis. NCCN Guidelines. Version 1.2015. 2 6/16/2015 EMETOGENIC POTENTIAL OF ORAL NCCN GUIDELINES: LOW RISK AGENTS: MODERATE TO HIGH Dexamethasone 12mg PO/IV daily OR Class Drug Metoclopramide 10-40mg PO/IV then every 4-6h prn OR Tyrosine kinase inhibitors Ceritinib Crizotinib Prochlorperazine 10mg PO/IV then every 6h prn OR Lenvatinib 5-HT3 antagonist Alkylating agents Busulfan (≥4mg/day) . Dolasetron 100mg PO daily Cyclophosphamide (≥100mg/m2/day) . Granisetron 1-2mg PO daily Estramustine . Ondansetron 8-16mg PO daily Temozolomide (>75mg/m2/day) Procarbazine Lomustine Altretamine Other Etoposide Mitotane Olaparib Panobinostat Antiemesis. NCCN Guidelines. Version 1.2015. Vismodegib Antiemesis. NCCN Guidelines. Version 1.2015. EMETOGENIC POTENTIAL OF ORAL NCCN GUIDELINES: ORAL AGENTS: MINIMAL TO LOW CHEMOTHERAPY EMESIS PREVENTION Class Drug Class Drug Class Drug High to moderate risk Tyrosine Afatinib Alkylating agents Melphalan Other Bexarotene kinase Axitinib Busulfan Everolimus . Start 5-HT3 antagonist before chemotherapy and continue inhibitors (<4mg/day) Bosutinib Hydroxyurea daily Chlorambucil Dasatinib Idelalisib Temozolomide Tretinoin Erlotinib (≤75mg/m2/day) Palbociclib Low to minimal risk Cabozantinib Cyclophosphamide Imatinib (<100mg/m2/day) Topotecan . PRN recommended Lapatinib Vorinostat Antimetabolites Mercaptopurine . Start antiemetic before chemotherapy and continue daily if Nilotinib Thioguanine nausea or vomiting occurs Ibrutinib Fludarabine Trametinib . Metoclopramide prn Capecitabine Vemurafenib Methotrexate . Prochlorperazine prn Pazopanib Immunomodulators Lenalidomide . Haloperidol prn Ponatinib Pomalidomide Regorafenib . 5-HT3 antagonist prn Thalidomide Ruxolitinib Sorafeib Antiemesis. NCCN Guidelines. Version 1.2015. Sunitinib Antiemesis. NCCN Guidelines. Version 1.2015. NCCN GUIDELINES: ANTICIPATORY NCCN GUIDELINES: BREAKTHROUGH NAUSEA/VOMITING Olanzapine 10mg PO daily for 3 days Behavioral therapy Lorazepam 0.5-2mg PO/SL/IV q6h Acupuncture/acupressure Dronabinol 5-10mg PO q3-6h Anxiolytic therapy Haloperidol 0.5-2mg PO/IV q4-6h . Alprazolam 0.5-1mg or lorazepam 0.5-2mg PO Scopolamine patch q72h . Night before treatment and repeated 1-2h before Prochlorperazine 25mg PR q12h or 10mg PO/IV q6h chemotherapy Promethazine 25mg PTR q6h or 12.5-25mg PO/IV every 4-6h Dexamethasone 12mg PO/IV daily Dolasetron 100mg PO daily Granisetron 1-2mg PO daily or 1mg PO bid or 0.01mg/kg IV daily Ondansetron 16mg PO/IV daily Antiemesis. NCCN Guidelines. Version 1.2015. Antiemesis. NCCN Guidelines. Version 1.2015. 3 6/16/2015 ETIOLOGY Causes of constipation in cancer patients . Diet . Inadequate fluid intake or fiber intake . Lack of exercise . The tumor itself . Drug therapy CONSTIPATION . Comorbidities such as organ failure, decreased mobility, and depression . Environmental factors National Cancer Institute. http://www.cancer.gov/about-cancer/treatment/side-effects/constipation/gi-complications-hp-pdq#section/all DRUGS AND CONSTIPATION CHEMOTHERAPY AND CONSTIPATION May be the result of autonomic neuropathy causing decreased Phenothiazines Antacids motility Inflammatory neuropathy has been demonstrated with Anticholinergics Diuretics ipilimumab Drugs associated with chemotherapy-induced constipation . Vinca alkaloids (vinblastine, vincristine, vinorelbine) . Taxanes (paclitaxel, docetaxel, cabazitaxel) Iron Opioids supplements . Thalidomide . Cisplatin Can be exacerbated by concomitant opioid use Chemotherapy Constipation Sedatives National Cancer Institute. http://www.cancer.gov/about-cancer/treatment/side-effects/constipation/gi-complications-hp-pdq#section/all Gibson RJ, Keefe DMK. Support Care Cancer 2006;14:890-900. Shailender B, Huber B, Upton MP et al. J Immunother. 2009;32:203-5. PashankarP, Season JH, McNamara J et al. J Pediatr Hematol Oncol 2011;33:e300-3. National Cancer Institute. http://www.cancer.gov/about-cancer/treatment/side-effects/constipation/gi-complications-hp-pdq#section/all NONPHARMACOLGIC MANAGEMENT DRUG THERAPY Increase dietary fiber Opioid-induced constipation . Fruit . Prevent with stimulant and stool softener (e.g., senna 8.6mg and . Green, leafy vegetables docusate 50mg two tablets daily) . Whole grains . If patient experiences constipation, increase dose and add agent Increase fluid intake . Miralax 17g . Milk of magnesia Exercise regularly Avoid rectal agents in cancer patients at risk for thrombocytopenia, neutropenia, or mucositis Lactulose has been successful in vincristine-induced constipation National Cancer Institute. http://www.cancer.gov/about-cancer/treatment/side-effects/constipation/gi-complications-hp-pdq#section/all National Cancer Institute. http://www.cancer.gov/about-cancer/treatment/side-effects/constipation/gi-complications-hp-pdq#section/all Harriis AC, Jackson JM.. Med J Aust. 1977;2:573-4. 4 6/16/2015 Mechanism Onset Precautions Dose Bulk Hold water in GI 12-24h, up Hydrate, avoid in Methylcellulose 5-20ml tid producers tract, soften to 72h obstruction Psyllium 1 tbsp 1-3 times stool daily NCCN GUIDELINES: PREVENTION Saline High osmolarity 0.5-3h May alter fluid and Milk of magnesia 10-20ml laxatives pulls water into electrolyte balance conc or 15-30ml regular, intestines magnesium citrate 240ml Increase fluids and dietary fiber Stimulant Increase motor 6-10h May cause cramping, Senna 2 tablets, bisacodyl Exercise laxatives activity of dependency 10-15mg PO or 10mg PR bowels Prophylactic stimulant laxative +/- stool softener Lubricant Lubricate 6-8h Aspiration potential, Mineral oil 5-30ml at bedtime Titrate up with goal of 1 non-forced bowel movement laxatives intestinal prevents absorption of mucosa oil-soluble drugs every 1-2 days Stool Promote water 3 days Increases mineral oil Docusate sodium 50-240mg
Recommended publications
  • MASCC/ESMO ANTIEMETIC GUIDELINE 2016 with Updates in 2019

    MASCC/ESMO ANTIEMETIC GUIDELINE 2016 with Updates in 2019

    1 ANTIEMETIC GUIDELINES: MASCC/ESMO MASCC/ESMO ANTIEMETIC GUIDELINE 2016 With Updates in 2019 Organizing and Overall Meeting Chairs: Matti Aapro, MD Richard J. Gralla, MD Jørn Herrstedt, MD, DMSci Alex Molassiotis, RN, PhD Fausto Roila, MD © Multinational Association of Supportive Care in CancerTM All rights reserved worldwide. 2 ANTIEMETIC GUIDELINES: MASCC/ESMO These slides are provided to all by the Multinational Association of Supportive Care in Cancer and can be used freely, provided no changes are made and the MASCC and ESMO logos, as well as date of the information are retained. For questions please contact: Matti Aapro at [email protected] Chair, MASCC Antiemetic Study Group or Alex Molassiotis at [email protected] Past Chair, MASCC Antiemetic Study Group 3 ANTIEMETIC GUIDELINES: MASCC/ESMO Consensus A few comments on this guideline set: • This set of guideline slides represents the latest edition of the guideline process. • This set of slides has been endorsed by the MASCC Antiemetic Guideline Committee and ESMO Guideline Committee. • The guidelines are based on the votes of the panel at the Copenhagen Consensus Conference on Antiemetic Therapy, June 2015. • Latest version: March 2016, with updates in 2019. 4 ANTIEMETIC GUIDELINES: MASCC/ESMO Changes: The Steering Committee has clarified some points: 2016: • A footnote clarified that aprepitant 165 mg is approved by regulatory authorities in some parts of the world ( although no randomised clinical trial has investigated this dose ). Thus use of aprepitant 80 mg in the delayed phase is only for those cases where aprepitant 125 mg is used on day 1. • A probable modification in pediatric guidelines based on the recent Cochrane meta-analysis is indicated.
  • Efficacy of Low Level Laser Therapy in Oral Mucositis

    Efficacy of Low Level Laser Therapy in Oral Mucositis

    Mini Review JOJ Nurse Health Care Volume 9 Issue 5 - November 2018 Copyright © All rights are reserved by Clélea de Oliveira Calvet DOI: 10.19080/JOJNHC.2018.09.555774 Efficacy of Low Level Laser Therapy in Oral Mucositis Graça Maria Lopes Mattos¹, Cayara Mattos Costa²and Clélea de Oliveira Calvet3* 1CEUMA University, Brazil ²Federal University of Maranhão, Brazil 3Integrated Clinic Hospital, Brazil Submission: November 02, 2018; Published: November 30, 2018 *Corresponding author: Clélea de Oliveira Calvet , Integrated Clinic Hospital, Maranhão, Brazil Abstract Patients submitted to radiotherapy or chemotherapy induced antineoplastic therapy have as their sequel oral mucositis, which is the main complication arising from the treatment. Laser therapy is a modality that has grown in recent years, with evidences of significant improvements thein the lesion. prevention A literature and treatment review was of oralconducted mucositis. with This seven study publications aims to show in Portuguese the benefits and of low-level English in laser PubMed therapy and application SciELO databases, in patients from submitted 2008 to to antineoplastic therapy and present oral mucositis by means of an integrative literature review on the use of low-level laser to prevent and treat effects.2018 and a summary table was prepared. It was observed that low-level laser therapy is an effective tool in the prevention and treatment of oral mucositis in cancer patients, bringing benefits such as: reduction of pain and severity of the lesion and anti-inflammatory,
  • Clinical Practice Guideline for Emergency Department Ketamine Dissociative Sedation: 2011 Update

    Clinical Practice Guideline for Emergency Department Ketamine Dissociative Sedation: 2011 Update

    PAIN MANAGEMENT/CONCEPTS Clinical Practice Guideline for Emergency Department Ketamine Dissociative Sedation: 2011 Update Steven M. Green, MD, Mark G. Roback, MD, Robert M. Kennedy, MD, Baruch Krauss, MD, EdM From the Department of Emergency Medicine, Loma Linda University Medical Center and Children’s Hospital, Loma Linda, CA (Green); the Department of Pediatrics, University of Minnesota, Minneapolis, MN (Roback); the Division of Emergency Medicine, St. Louis Children’s Hospital, Washington University, St. Louis, MO (Kennedy); and the Division of Emergency Medicine, Children’s Hospital Boston and Department of Pediatrics, Harvard Medical School, Boston, MA (Krauss). We update an evidence-based clinical practice guideline for the administration of the dissociative agent ketamine for emergency department procedural sedation and analgesia. Substantial new research warrants revision of the widely disseminated 2004 guideline, particularly with respect to contraindications, age recommendations, potential neurotoxicity, and the role of coadministered anticholinergics and benzodiazepines. We critically discuss indications, contraindications, personnel requirements, monitoring, dosing, coadministered medications, recovery issues, and future research questions for ketamine dissociative sedation. [Ann Emerg Med. 2011;xx:xxx.] 0196-0644/$-see front matter Copyright © 2011 by the American College of Emergency Physicians. doi:10.1016/j.annemergmed.2010.11.030 INTRODUCTION thalamocortical and limbic systems, effectively dissociating the The dissociative
  • Antiemetics/Antivertigo Agents

    Antiemetics/Antivertigo Agents

    Antiemetic Agents Therapeutic Class Review (TCR) May 1, 2019 No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, recording, digital scanning, or via any information storage or retrieval system without the express written consent of Magellan Rx Management. All requests for permission should be mailed to: Magellan Rx Management Attention: Legal Department 6950 Columbia Gateway Drive Columbia, Maryland 21046 The materials contained herein represent the opinions of the collective authors and editors and should not be construed to be the official representation of any professional organization or group, any state Pharmacy and Therapeutics committee, any state Medicaid Agency, or any other clinical committee. This material is not intended to be relied upon as medical advice for specific medical cases and nothing contained herein should be relied upon by any patient, medical professional or layperson seeking information about a specific course of treatment for a specific medical condition. All readers of this material are responsible for independently obtaining medical advice and guidance from their own physician and/or other medical professional in regard to the best course of treatment for their specific medical condition. This publication, inclusive of all forms contained herein, is intended to be educational in nature and is intended to be used for informational purposes only. Send comments and suggestions to [email protected]. May 2019 Proprietary Information. Restricted Access – Do not disseminate or copy without approval. © 2004-2019 Magellan Rx Management. All Rights Reserved. 3 FDA-APPROVED INDICATIONS Drug Manufacturer Indication(s) NK1 receptor antagonists aprepitant capsules generic, Merck In combination with other antiemetic agents for: (Emend®)1 .
  • Revised Use-Function Classification (2007)

    Revised Use-Function Classification (2007)

    INTERNATIONAL PROGRAMME ON CHEMICAL SAFETY IPCS INTOX Data Management System (INTOX DMS) Revised Use-Function Classification (2007) The Use-Function Classification is used in two places in the INTOX Data Management System: the Communication Record and the Agent/Product Record. The two records are linked: if there is an agent record for a Centre Agent that is the subject of a call, the appropriate Intended Use-Function can be selected automatically in the Communication Record. The Use-Function Classification is used when generating reports, both standard and customized, and for searching the case and agent databases. In particular, INTOX standard reports use the top level headings of the Intended Use-Functions that were selected for Centre Agents in the Communication Record (e.g. if an agent was classified as an Analgesic for Human Use in the Communication Record, it would be logged as a Pharmaceutical for Human Use in the report). The Use-Function classification is very important for ensuring harmonized data collection. In version 4.4 of the software, 5 new additions were made to the top levels of the classification provided with the system for the classification of organisms (items XIV to XVIII). This is a 'convenience' classification to facilitate searching of the Communications database. A taxonomic classification for organisms is provided within the INTOX DMS Agent Explorer. In May/June 2006 INTOX users were surveyed to find out whether they had made any changes to the Use-Function Classification. These changes were then discussed at the 4th and 5th Meetings of INTOX Users. Version 4.5 of the INTOX DMS includes the revised pesticides classification (shown in full below).
  • Drugs to Avoid in Patients with Dementia

    Drugs to Avoid in Patients with Dementia

    Detail-Document #240510 -This Detail-Document accompanies the related article published in- PHARMACIST’S LETTER / PRESCRIBER’S LETTER May 2008 ~ Volume 24 ~ Number 240510 Drugs To Avoid in Patients with Dementia Elderly people with dementia often tolerate drugs less favorably than healthy older adults. Reasons include increased sensitivity to certain side effects, difficulty with adhering to drug regimens, and decreased ability to recognize and report adverse events. Elderly adults with dementia are also more prone than healthy older persons to develop drug-induced cognitive impairment.1 Medications with strong anticholinergic (AC) side effects, such as sedating antihistamines, are well- known for causing acute cognitive impairment in people with dementia.1-3 Anticholinergic-like effects, such as urinary retention and dry mouth, have also been identified in drugs not typically associated with major AC side effects (e.g., narcotics, benzodiazepines).3 These drugs are also important causes of acute confusional states. Factors that may determine whether a patient will develop cognitive impairment when exposed to ACs include: 1) total AC load (determined by number of AC drugs and dose of agents utilized), 2) baseline cognitive function, and 3) individual patient pharmacodynamic and pharmacokinetic features (e.g., renal/hepatic function).1 Evidence suggests that impairment of cholinergic transmission plays a key role in the development of Alzheimer’s dementia. Thus, the development of the cholinesterase inhibitors (CIs). When used appropriately, the CIs (donepezil [Aricept], rivastigmine [Exelon], and galantamine [Razadyne, Reminyl in Canada]) may slow the decline of cognitive and functional impairment in people with dementia. In order to achieve maximum therapeutic effect, they ideally should not be used in combination with ACs, agents known to have an opposing mechanism of action.1,2 Roe et al studied AC use in 836 elderly patients.1 Use of ACs was found to be greater in patients with probable dementia than healthy older adults (33% vs.
  • Yorkshire Palliative Medicine Clinical Guidelines Group Guidelines on the Use of Antiemetics Author(S): Dr Annette Edwards (Chai

    Yorkshire Palliative Medicine Clinical Guidelines Group Guidelines on the Use of Antiemetics Author(S): Dr Annette Edwards (Chai

    Yorkshire Palliative Medicine Clinical Guidelines Group Guidelines on the use of Antiemetics Author(s): Dr Annette Edwards (Chair) and Deborah Royle on behalf of the Yorkshire Palliative Medicine Clinical Guidelines Group Overall objective : To provide guidance on the evidence for the use of antiemetics in specialist palliative care. Search Strategy: Search strategy: Medline, Embase and Cinahl databases were searched using the words nausea, vomit$, emesis, antiemetic and drug name. Review Date: March 2008 Competing interests: None declared Disclaimer: These guidelines are the property of the Yorkshire Palliative Medicine Clinical Guidelines Group. They are intended to be used by qualified, specialist palliative care professionals as an information resource. They should be used in the clinical context of each individual patient’s needs. The clinical guidelines group takes no responsibility for any consequences of any actions taken as a result of using these guidelines. Contact Details: Dr Annette Edwards, Macmillan Consultant in Palliative Medicine, Department of Palliative Medicine, Pinderfields General Hospital, Aberford Road, Wakefield, WF1 4DG Tel: 01924 212290 E-mail: [email protected] 1 Introduction: Nausea and vomiting are common symptoms in patients with advanced cancer. A careful history, examination and appropriate investigations may help to infer the pathophysiological mechanism involved. Where possible and clinically appropriate aetiological factors should be corrected. Antiemetics are chosen based on the likely mechanism and the neurotransmitters involved in the emetic pathway. However, a recent systematic review has highlighted that evidence for the management of nausea and vomiting in advanced cancer is sparse. (Glare 2004) The following drug and non-drug treatments were reviewed to assess the strength of evidence for their use as antiemetics with particular emphasis on their use in the palliative care population.
  • Severe, Ulcerative, Lichenoid Mucositis Associated with Secukinumab

    Severe, Ulcerative, Lichenoid Mucositis Associated with Secukinumab

    CASE REPORT Severe, ulcerative, lichenoid mucositis associated with secukinumab Jordan M. Thompson, BS,a Lisa M. Cohen, MD,b Catherine S. Yang, MD,c and George Kroumpouzos, MD, PhDc,d Providence, Rhode Island, and Lexington and South Weymouth, Massachusetts Key words: drug eruption; interleukin-17; lichenoid mucositis; secukinumab; tumor necrosis factor-a. INTRODUCTION Abbreviations used: Secukinumab is a new human monoclonal anti- body targeting interleukin (IL)-17A, a cytokine EM: erythema multiforme IL: interleukin involved in the pathogenesis of psoriasis. The US LP: lichen planus Food and Drug Administration approved secukinu- MMP: mucous membrane pemphigoid mab for psoriasis in 2015. Because the medication PV: pemphigus vulgaris TNF-a: tumor necrosis factor-a has been on the market for a short time, adverse events involving the oral mucosa are rarely reported. We report a case of severe, ulcerative, lichenoid mucositis associated with secukinumab use. cells (Figs 2 and 3). The presence of eosinophils and deeper inflammatory infiltrate (Fig 2) suggested a lichenoid drug eruption. Direct immunofluores- CASE REPORT cence of perilesional mucosa found nonspecific A 62-year-old white man underwent follow-up for basal epithelium staining for C3, IgG, and IgM. The long-standing, intractable, erythrodermic psoriasis. patient started using 0.1% triamcinolone in Orabase He did not respond to tumor necrosis factor (TNF) paste. It was not until approximately 6 weeks from inhibitors such as adalimumab and etanercept and secukinumab discontinuation and 1 week of steroid could not tolerate cyclosporine. Because metho- paste use that the labial lesions showed substantial trexate was only mildly efficacious, secukinumab improvement. was added.
  • Photobiomodulation for Taste Alteration

    Photobiomodulation for Taste Alteration

    Entry Photobiomodulation for Taste Alteration Marwan El Mobadder and Samir Nammour * Department of Dental Science, Faculty of Medicine, University of Liège, 4000 Liège, Belgium; [email protected] * Correspondence: [email protected]; Tel.: +32-474-507-722 Definition: Photobiomodulation (PBM) therapy employs light at red and near-infrared wavelengths to modulate biological activity. The therapeutic effect of PBM for the treatment or management of several diseases and injuries has gained significant popularity among researchers and clinicians, especially for the management of oral complications of cancer therapy. This entry focuses on the current evidence on the use of PBM for the management of a frequent oral complication due to cancer therapy—taste alteration. Keywords: dysgeusia; cancer complications; photobiomodulation; oral mucositis; laser therapy; taste alteration 1. Introduction Taste is one of the five basic senses, which also include hearing, touch, sight, and smell [1]. The three primary functions of this complex chemical process are pleasure, defense, and sustenance [1,2]. It is the perception derived from the stimulation of chemical molecule receptors in some specific locations of the oral cavity to code the taste qualities, in order to perceive the impact of the food on the organism, essentially [1,2]. An alteration Citation: El Mobadder, M.; of this typical taste functioning can be caused by various factors and is usually referred to Nammour, S. Photobiomodulation for as taste impairments, taste alteration, or dysgeusia [3,4]. Taste Alteration. Encyclopedia 2021, 1, In cancer patients, however, the impact of taste alteration or dysgeusia on the quality 240–248. https://doi.org/10.3390/ of life (QoL) is substantial, resulting in significant weight loss, malnutrition, depression, encyclopedia1010022 compromising adherence to cancer therapy, and, in severe cases, morbidity [5].
  • Intracellular Vomit Signals and Cascades Downstream of Emetic Receptors: Evidence from the Least Shrew (Cryptotis Parva) Model of Vomiting

    Intracellular Vomit Signals and Cascades Downstream of Emetic Receptors: Evidence from the Least Shrew (Cryptotis Parva) Model of Vomiting

    Mini Review Remedy Open Access Published: 31 Oct, 2017 Intracellular Vomit Signals and Cascades Downstream of Emetic Receptors: Evidence from the Least Shrew (Cryptotis parva) Model of Vomiting Zhong W and Darmani NA* Department of Basic Medical Sciences, Western University of Health Sciences, CA 91766, USA Abstract Nausea and vomiting are often considered as stressful symptoms of many diseases and drugs. In fact they are the most feared and debilitating side-effects of many cancer chemotherapeutics and the main cause of patient noncompliance. Despite years of substantial research, the intracellular emetic signals are at best poorly understood or remain unknown. Among different receptor-mediated emetic signaling cascades, one potential converging signal appears to be changes in the cytosolic concentration of Ca2+. In this editorial, we focus on Ca2+-related intracellular signals underlying emesis mediated by various emetogens. This strategy will help us understand common signaling mechanisms downstream of diverse emetogens and should therefore promote development of new antiemetics for the treatment nausea and vomiting caused by diverse diseases, drugs, as well as viruses and bacterial infections. Keywords: Emetogens; Nausea; Intracellular emetic signals Introduction Nausea and vomiting (emesis) can be both a reason and/or symptoms of diseases, drugs OPEN ACCESS (e.g. chemotherapeutics [1-3], opiates [4]), conditions (pregnancy [5], motion sickness [6], food poisoning [7]), as well as bacterial [8] and viral infections [9]. Treatment of these symptoms require *Correspondence: millions of patient visits per year to the doctors’ office or hospitals in the USA [10,11]. These Nissar A. Darmani, Department of symptoms are an important gastrointestinal problem which worsens the both quality of patient Basic Medical Sciences, College of life and treatment.
  • The Vomiting Center and the Chemoreceptor Trigger Zone

    The Vomiting Center and the Chemoreceptor Trigger Zone

    Pharmacologic Control of Vomiting Todd R. Tams, DVM, Dipl. ACVIM VCA West Los Angeles Animal Hospital Pharmacologic Control of Acute Vomiting Initial nonspecific management of vomiting includes NPO (in minor cases a 6-12 hour period of nothing per os may be all that is required), fluid support, and antiemetics. Initial feeding includes small portions of a low fat, single source protein diet starting 6-12 hours after vomiting has ceased. Drugs used to control vomiting will be discussed here. The most effective antiemetics are those that act at both the vomiting center and the chemoreceptor trigger zone. Vomiting is a protective reflex and when it occurs only occasionally treatment is not generally required. However, patients that continue to vomit should be given antiemetics to help reduce fluid loss, pain and discomfort. For many years I strongly favored chlorpromazine (Thorazine), a phenothiazine drug, as the first choice for pharmacologic control of vomiting in most cases. The HT-3 receptor antagonists ondansetron (Zofran) and dolasetron (Anzemet) have also been highly effective antiemetic drugs for a variety of causes of vomiting. Metoclopramide (Reglan) is a reasonably good central antiemetic drug for dogs but not for cats. Maropitant (Cerenia) is a superior broad spectrum antiemetic drug and is now recognized as an excellent first choice for control of vomiting in dogs. Studies and clinical experience have now also shown maropitant to be an effective and safe antiemetic drug for cats. While it is labeled only for dogs, clinical experience has shown it is safe to use the drug in cats as well. Maropitant is also the first choice for prevention of motion sickness vomiting in both dogs and cats.
  • Oral Mucositis

    Oral Mucositis

    Division of Oral Medicine and Dentistry Oral Mucositis What is oral mucositis? Oral mucositis is a common side efect of many drugs used to Treatment with a class of chemotherapy (and treat cancer (chemotherapy). It is also common among patients immunosuppressive) agents called “mammalian target of receiving radiation therapy for cancers of the mouth, salivary rapamycin inhibitors”, or mTOR inhibitors (such as glands, sinuses and throat. Mucositis occurs when the cells and Rapamune and Afnitor), is also associated with development tissues of the mouth are injured by cancer treatment, which of oral ulcers. Unlike mucositis described above, this is cannot distinguish between ‘good’ normal cells or ‘bad’ cancer characterized by painful ulcers that look like canker sores. Tese cells. As a result the lining of the mouth breaks down and forms typically develop within the frst 1-2 weeks of mTOR inhibitor painful ulcers. Te severity of mouth ulcers may vary among therapy and tend to subside afer a few weeks even with patients with some patients being more able to tolerate them ongoing therapy. than others. Such ulcers can occur anywhere in the mouth, but Oral mucositis is not infectious in nature and you cannot spread are most common on the tongue, inside cheeks, lips and sof it to family or friends. palate (very back of the mouth). Although mucositis may be dramatic for a period of time while you are being treated, the How do we know it is oral mucositis? ulcers almost always heal by themselves within a few weeks of Mucositis is common. Your doctor can generally make a completing cancer treatment.